Company Overview of Akebia Therapeutics, Inc.
Akebia Therapeutics, Inc., a biopharmaceutical company, focuses on the development and commercialization of proprietary therapeutics based on hypoxia inducible factor (HIF) biology for patients with kidney disease. Its lead product candidate is AKB-6548, an oral therapy which has completed a Phase 2b study for the treatment of anemia related to chronic kidney disease in non-dialysis patients, as well as tested in a Phase 2 study for the treatment of anemia in patients undergoing dialysis. The company was founded in 2007 and is headquartered in Cambridge, Massachusetts.
245 First Street
Cambridge, MA 02142
Founded in 2007
Key Executives for Akebia Therapeutics, Inc.
Chief Executive Officer, President and Director
Total Annual Compensation: $552.3K
Chief Financial Officer, Senior Vice President and Treasurer
Total Annual Compensation: $415.9K
Chief Medical Officer and Senior Vice President
Total Annual Compensation: $181.5K
Compensation as of Fiscal Year 2014.
Akebia Therapeutics, Inc. Key Developments
Akebia Therapeutics, Inc. Presents at 18th Annual BIO CEO & Investor Conference 2016, Feb-08-2016 11:30 AM
Jan 18 16
Akebia Therapeutics, Inc. Presents at 18th Annual BIO CEO & Investor Conference 2016, Feb-08-2016 11:30 AM. Venue: The Waldorf Astoria, 301 Park Avenue, New York, New York, United States. Speakers: John P. Butler, Chief Executive Officer, President and Director.
Akebia Therapeutics To Sell Its Stock
Jan 5 16
Akebia Therapeutics, Inc. (NasdaqGM:AKBA) is looking to sell $75 million in stock.
Akebia Therapeutics Inc. Initiates Phase 3 PRO2TECT™ Program
Jan 4 16
Akebia Therapeutics Inc. announced several corporate and clinical developments consistent with its objectives for 2015, including dosing the first patient in its global Phase 3 PRO2TECT program in December. This program is evaluating vadadustat (formerly AKB-6548) in non-dialysis patients with anemia related to chronic kidney disease (NDD-CKD). In addition, the U.S. Food and Drug Administration (FDA) recently opened Akebia's Investigational New Drug (IND) application, allowing the company to initiate a Phase 1 clinical study of AKB-6899, an orally-available HIF stabilizer, in oncology. The company also made progress with its intellectual property efforts in Japan for vadadustat. The PRO2TECT Phase 3 program includes two separate studies that will collectively enroll approximately 3,100 NDD-CKD patients across 500 sites globally. The first patient was recently dosed in the PRO2TECT correction study, which is enrolling anemic patients not currently being treated with recombinant erythropoiesis stimulating agents (rESAs). The PRO2TECT conversion study includes patients currently receiving rESA who will be converted to either vadadustat or the active control with the goal of maintaining their baseline hemoglobin levels. Both studies include a 1:1 randomization and an open label, active-control, non-inferiority design. Primary endpoints include an efficacy assessment of the hemoglobin response and cardiovascular safety as measured by major adverse cardiovascular events. The PRO2TECT program is designed to support registration in major markets worldwide and to collect the data required to establish a new standard of care for chronic kidney disease (CKD) patients. The company expects to complete enrollment in late 2017.
Similar Private Companies By Industry
Recent Private Companies Transactions
|No transactions available in the past 12 months.|